Printer Friendly

GENSIA ANNOUNCES COMPLETION OF ARASINE PHASE 3 TRIAL

 GENSIA ANNOUNCES COMPLETION OF ARASINE PHASE 3 TRIAL
 SAN DIEGO, June 22 /PRNewswire/ -- Gensia Pharmaceuticals


(NASDAQ: GNSA) today announced that it has completed patient enrollment in a multicenter clinical trial in Western Europe and Canada with Arasine(TM) (acadesine) for use in patients undergoing coronary artery bypass surgery. A U.S. multicenter Phase 3 clinical trial with Arasine was completed in April of this year. Approximately 1,400 patients in total were enrolled in the U.S. and international multicenter studies, according to David F. Hale, chairman, president and chief executive officer.
 "We expect data consolidation, review and analysis and preparation of the New Drug Application (NDA) for Arasine to take approximately six months to complete," said Hale. "We plan to submit the Arasine NDA to the Food and Drug Administration by the end of 1992 followed by the submission of a Marketing Authorization Application (MAA) to the European Economic Community under the procedure established by the European Committee for Proprietary Medicinal Products (CPMP). A Canadian regulatory filing for Arasine is planned for the first quarter of 1993."
 The primary objectives of the Phase 3 clinical trials with Arasine in patients undergoing coronary artery bypass surgery are to demonstrate that Arasine reduces the incidence of acute myocardial infarction (heart attacks) and the overall incidence of adverse cardiovascular outcomes associated with the surgery. The secondary objectives of the Phase 3 clinical trials are to investigate whether Arasine can improve cardiac function, reduce the overall incidence, severity and duration of ischemia and improve patient recovery after surgery, thus potentially providing significant clinical benefits and cost savings.
 The company expects that data from the U.S. Arasine Phase 3 clinical trial will be submitted for presentation at a major medical meeting in the first quarter of 1993 and that data from the international Phase 3 trial will be submitted for presentation at a medical meeting in mid-1993.
 According to Hale, "In addition to providing important clinical data on the efficacy of Arasine in patients undergoing coronary artery bypass surgery, the Phase 3 clinical trials should supply a large data base of information about adverse perioperative cardiovascular outcomes associated with coronary artery bypass surgery. We anticipate that several papers will be written by the clinical investigators who participated in these studies and that these papers would be submitted late this year for publication in medical journals in mid-1993."
 Gensia is also conducting a Phase 2 clinical with Arasine to investigate dosing regimens in patients undergoing non-cardiac surgery. The company expects to initiate a multicenter Phase 3 clinical trial with Arasine in the last half of 1992 in patients undergoing non-cardiac surgery who are at high risk of developing cardiovascular complications.
 Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
 -0- 6/22/92
 /CONTACT: Martha L. Hough or Elizabeth A. Gard of Gensia Pharmaceuticals, 619-546-8300/
 (GNSA) CO: Gensia Pharmaceuticals Inc. ST: California IN: MTC SU: KJ-JL -- SD001 -- 2250 06/22/92 09:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1992
Words:507
Previous Article:ICOS ANNOUNCES RESEARCH AGREEMENT WITH DOHENY EYE INSTITUTE
Next Article:HERBALIFE CORRECTS JUNE 17 ANNOUNCEMENT
Topics:


Related Articles
GENSIA INITIATES PHASE 2 CLINICAL TRIAL WITH ARASINE IN NON-CARDIAC SURGERY
ARBUTAMINE CLINICAL AND PRECLINICAL DATA ABSTRACTS PUBLISHED IN CIRCULATION
GENSIA TO PROCEED AS PLANNED WITH ARASINE REGULATORY FILINGS IN UNITED STATES AND EUROPE
GENSIA FILES NDA FOR ARASINE AS PLANNED WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
GENSIA FILES REGULATORY SUBMISSIONS FOR ARASINE AS PLANNED IN EUROPEAN MARKETS
GENSIA AND ARAMED INITIATE PHASE 1 WITH ARA COMPOUND
GENSIA ANNOUNCES DATA FROM MULTICENTER STUDY WITH PROTARA IN CORONARY ARTERY BYPASS SURGERY
GENSIA INITIATES PHASE 1 CLINICAL TRIAL WITH GP3269
Atrix to Continue Development of Cancer Therapy
Atrix To Continue Development of Cancer Therapy

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters